Search results
Welcome to Roche Singapore. For professionals. Career. This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.
Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management.
Explore exciting job opportunities at Roche Singapore.
Phone: Discover more. This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.
Roche Diagnostics develops innovative products and services that address the prevention, diagnosis, monitoring, screening and treatment of diseases.
As the leading provider in diagnostics, we contribute a broad range of innovative products and services that support early detection, prevention, diagnosis and treatment of diseases. Our focus and emphasis on novel and meaningful advances in diagnostic technologies remains core to our strategy today.
Roche Diagnostics is the diagnostic division of F. Hoffmann-La Roche which manufactures equipment and reagents for research and medical diagnostic applications. Learn how in vitro diagnostics are an integral part of decision-making along the entire continuum of a patient’s health or disease.
In 2022, a collaboration between Roche and the Singapore Translational Cancer Consortium (STCC), a nationally coordinated consortium designed to synergise cancer research capabilities, was established to drive adoption of a ‘precision oncology’ care model.
As a pioneer in healthcare, we have been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.
Jul 18, 2022 · Singapore, 18 July 2022 – The Singapore Eye Research Institute (SERI) and Roche today announced Vabysmo® (faricimab) was approved for use by Singapore's Health Sciences Authority for the treatment of neovascular age-related macular degeneration (nAMD) [1] and diabetic macular edema (DME) [2] in June.
